Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

SITAG-50 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/SITAG-50

Approved

STANDARD

SITAG-50

Bafna Pharmaceuticals Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: a2f700febf834c91
Company: Bafna Pharmaceuticals Ltd.
Type: Standard

Approval Details

Approval Id: a2f700febf834c91
Drug Approval Philippines Name: SITAG-50
Product Name: SITAG-50
Registration Number: DRP-6383
Brand Name: SITAG-50
Generic Name: SITAGLIPTIN (as phosphate monohydrate)
Dosage Form: Film-Coated Tablet
Dosage Strength: 50mg
Manufacturer: Bafna Pharmaceuticals Ltd.
Importer: MedEthix, Inc.
Distributor: Corbridge Group Phils. Inc.
Issuance Date: 24 January 2025
Expiry Date: 09 October 2025
Pharmacologic Category: Oral Hypoglycemic
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

a2f700febf834c91

Type

Standard

Back to Philippines FDA Approvals